Compare ARMP & JFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARMP | JFIN |
|---|---|---|
| Founded | N/A | 2011 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.7M | 330.9M |
| IPO Year | 1996 | 2018 |
| Metric | ARMP | JFIN |
|---|---|---|
| Price | $8.20 | $6.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 35.3K | ★ 75.7K |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.52% |
| EPS Growth | ★ 53.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $5.73 |
| 52 Week High | $13.75 | $18.70 |
| Indicator | ARMP | JFIN |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 45.55 |
| Support Level | $7.75 | $5.90 |
| Resistance Level | $8.36 | $6.53 |
| Average True Range (ATR) | 0.59 | 0.42 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 85.53 | 45.16 |
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.